Soluble mesothelin-related peptide (SMRP) is a biomarker that has been proposed for differential diagnosis from pleural metastatic cancer, as well as prognosis and treatment monitoring of malignant pleural mesothelioma (MM). The aim of this study was to evaluate the role of SMRP in clinic management of MM. We assayed the SMRP concentrations in 354 subjects: 109 healthy volunteers with no history of exposure to asbestos, 26 patients with previous occupational asbestos exposure but who were free from pleural or parenchymal disease, 48 patients with asbestosis, 110 patients with pleural plaques, 25 patients with lung cancer, and 36 patients with MM. We also tested SMRP titers in 2 patients with MM at 5 different times of the disease, to evaluate the trend of the biomarker in the course of therapy. Our data confirm previous experiences with the use of SMRP as a diagnostic marker of MM. Low SMRP levels at diagnosis seem to have a positive prognostic significance.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5301/JBM.2011.8614 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Soluble mesothelin-related peptide as a prognosticator in pleural mesothelioma patients receiving checkpoint immunotherapy.
J Thorac Cardiovasc Surg
October 2024
Systems Onco-Immunology Laboratory, David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Tex; Division of Hemato-Oncology, Department of Medicine, Baylor College of Medicine, Houston, Tex; David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Tex. Electronic address:
Article Synopsis
- Immune checkpoint therapy (ICT) has changed the treatment landscape for malignant pleural mesothelioma (MPM), but nearly half of patients do not see benefits, emphasizing the need for predictive biomarkers.
- This study evaluated the prognostic value of serum soluble mesothelin-related peptide (SMRP) and PD-L1 levels in 125 MPM patients undergoing ICT, using statistical analyses to determine their impact on overall survival (OS).
- Results showed that higher pre-ICT SMRP levels are linked to poorer prognosis, with low levels indicating better survival outcomes, suggesting that SMRP could serve as a valuable biomarker for future MPM treatment studies.
Panel of serum biomarkers for differential diagnosis of idiopathic interstitial lung disease and interstitial lung disease-secondary to systemic autoimmune rheumatic disease.
PLoS One
October 2024
Department of Medicine, Surgery & Neurosciences, Rheumatology Unit, University of Siena, Siena, Italy.
Article Synopsis
- Researchers studied lung disease linked to autoimmune diseases and wanted to find helpful tests to diagnose it!
- They looked at 3,169 patients and measured specific substances in their blood, focusing on two types of lung disease!
- The study found that a substance called KL-6 was really useful for diagnosing lung disease, and using both blood tests and patient info could help doctors make better decisions!
Circulating SMRP and CA-125 before and after pleurectomy decortication for pleural mesothelioma.
Thorac Cancer
May 2024
The Thoracic Surgery Oncology Laboratory and the International Mesothelioma Program (http://www.impmeso.org), Division of Thoracic Surgery and the Lung Center, Brigham, and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Background: Tumor recurrence remains the main barrier to survival after surgery for pleural mesothelioma (PM). Soluble mesothelin-related protein (SMRP) and cancer antigen 125 (CA-125) are established blood-based biomarkers for monitoring PM. We prospectively studied the utility of these biomarkers after pleurectomy decortication (PD).
View Article and Find Full Text PDFMesothelin methylation, soluble mesothelin related protein levels and inflammation profiling in workers chronically exposed to naturally occurring asbestos fibers.
Transl Oncol
February 2024
Occupational Medicine, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Exposure to asbestiform fibers, including chrysotile and amphibole, is carcinogenic, causing malignant pleural mesothelioma (MPM) when inhaled. Some populations globally face Naturally Occurring Asbestos (NOA) exposure, leading to MPM cases like in Biancavilla, Italy, from Fluoro-edenite (FE) contamination. Studies show NOA exposure causes epigenetic changes, focusing on mesothelin methylation, an MPM marker, and altered inflammation, emphasizing the health risks of FE and asbestos.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!